THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT.

被引：0
|
作者：
Xin, Y. [1 ]
Collins, H. [1 ]
Cheng, F. [1 ]
Kwan, E. [1 ]
Ramanathan, S. [1 ]
Silverman, J. A. [1 ]
机构：
[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-049
引用
收藏
页码：S87 / S88
页数：2
相关论文
共 50 条
  • [31] Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment
    Li, Yan
    MacGorman, Kimberly
    Liu, Liangang
    Chen, Jian
    Hoffmann, Matthew
    Palmisano, Maria
    Zhou, Simon
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (07): : 785 - 796
  • [32] Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
    Custodio, Joseph M.
    Fordyce, Marshall
    Garner, William
    Vimal, Mona
    Ling, Kah Hiing J.
    Kearney, Brian P.
    Ramanathan, Srinivasan
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) : 5135 - 5140
  • [33] Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment
    Yang, Haijing
    Zhang, Min
    Chen, Yuancheng
    Ren, Hong
    Zhang, Hong
    Yu, Chen
    Lu, Jianda
    You, Li
    Yu, Jicheng
    Liang, Hong
    Xiao, Cuilan
    He, Zishuang
    Wu, Jufang
    Xue, Jun
    Zhang, Jing
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (07) : 1079 - 1086
  • [34] Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment
    Haijing Yang
    Min Zhang
    Yuancheng Chen
    Hong Ren
    Hong Zhang
    Chen Yu
    Jianda Lu
    Li You
    Jicheng Yu
    Hong Liang
    Cuilan Xiao
    Zishuang He
    Jufang Wu
    Jun Xue
    Jing Zhang
    [J]. European Journal of Clinical Pharmacology, 2022, 78 : 1079 - 1086
  • [35] Pharmacokinetics and safety following a single oral dose of niraparib in patients with moderate hepatic impairment.
    Akce, Mehmet
    El-Khoueiry, Anthony B.
    Piha-Paul, Sarina Anne
    Bacque, Emeline
    Pan, Peng
    Zhang, Zhi-Yi
    Ewesuedo, Reginald
    Gupta, Divya
    Milton, Ashley
    Judson, Patricia
    O'Bryant, Cindy L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Pharmacokinetics (PK) of garenoxacin in healthy subjects and in subjects with hepatic impairment.
    Noveck, RJ
    Vargas, R
    Russo, R
    Bello, A
    Gajjar, D
    Grasela, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P79 - P79
  • [37] The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment
    Nichols, A. I.
    Richards, L. S.
    Behrle, J. A.
    Posener, J. A.
    McGrory, S. B.
    Paul, J.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (01) : 3 - 13
  • [38] The pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran in patients with severe renal impairment.
    Eriksson, UG
    Samuelsson, O
    Attman, PO
    Mulec, H
    Johausson, S
    Frison, L
    Fager, G
    [J]. BLOOD, 2001, 98 (11) : 268A - 268A
  • [39] Pharmacokinetics of eslicarbazepine acetate in patients with moderate liver impairment.
    Maia, Joana
    Potgieter, J. Henk
    Almeida, Luis
    Soares-da-Silva, P.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1192 - 1192
  • [40] Pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects
    Li, Z.
    TenHoor, C.
    Marbury, T.
    Swan, S.
    Zhu, Y.
    Ticho, B.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (09) : 563 - 570
12345